Effects of Coenzyme Q10 (CoQ) in Parkinson Disease (QE3)

In: Beal MF, Henshaw DR, Jenks BG, Rosen BR, Schulz JB. Coenzyme Q10 and notame block strtal lesns produced by the mochondrl tox malonate. Ann Neurol. 1994 Dec;36(6):882-8. do 10.1002/ana.410360613. Beal MF, Matthews RT, Tleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyre (MPTP) duced loss of strtal dopame and dopamerg axons aged me. Bra Res. 1998 Feb 2;783(1):109-14. do 10.1016/s0006-8993(97)01192-x. Beal MF. Energets the pathogenes of neurodegenerate deases. Trends Neurosc 2000 Jul;23(7):298-304. do 10.1016/s0166-2236(00)01584-8. Beal MF. Coenzyme Q10 as a possle treatment for neurodegenerate deases. Free Rad Res. 2002 Apr;36(4):455-60. do 10.1080/10715760290021315. NDS NET-PD vestators. A randomed clal trl of coenzyme Q10 and GP1485 early Parkson dease. Neurology. 2007 Jan 2;68(1):20-8. do 10.1212/01.wnl.0000250355.28474.8e. Rava BM, Fagan SC, Hart RG, Hovga CA, Murphy DD, Dawson TM, Marler JR. Neuroprotecte agents for clal trls Parkson's dease: a systemat assessment. Neurology. 2003 Apr 22;60(8):1234-40. do 10.1212/01.wnl.0000058760.13152.1a. Shoulson Oakes D, Fahn S, Lang A, Langston JW, LeWt P, Olanow CW, Penney JB, Tanner C, Kburtz K, Rudolph A; Parkson Study Group. pact of sustaed deprenyl (selege) levodopa-treated Parkson's dease: a randomed placebo-controlled extensn of the deprenyl and tocopherol antxate therapy of parksonm trl. Ann Neurol. 2002 May;51(5):604-12. do 10.1002/ana.10191. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate wh the acts of complexes and / mochondr from parksonn and nonparksonn subjects. Ann Neurol. 1997 Aug;42(2):261-4. do 10.1002/ana.410420221. Shults CW, Beal MF, Fontae D, Nakano K, Haas RH. Absorptn, toleraby, and effects on mochondrl acty of oral coenzyme Q10 parksonn patnts. Neurology. 1998 Mar;50(3):793-5. do 10.1212/wnl.50.3.793. Shults CW, Oakes D, Kburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson Carter J, KompolK, Perlmutter JS, Reh S, Stern M, Watts RL, Kurlan R, Molho E, Harron M, Lew M; Parkson Study Group. Effects of coenzyme Q10 early Parkson dease: evence of slowg of the functnal decle. Arch Neurol. 2002 Oct;59(10):1541-50. do 10.1001/archneur.59.10.1541. Shults CW. Coenzyme Q10 neurodegenerate deases. Curr Med Chem. 2003 Oct;10(19):1917-21. do 10.2174/0929867033456882. Shults CW, Flt Beal M, Song D, Fontae D. Pot trl of hh dosages of coenzyme Q10 patnts wh Parkson's dease. Exp Neurol. 2004 Aug;188(2):491-4. do 10.1016/j.expneurol.2004.05.003. Lee , Cook NR, Gazno JM, Gordon D, Rker PM, Manson JE, Hennekens CH, Burg JE. Vam E the prary preventn of cardvascular dease and cancer: the Women's Health Study: a randomed controlled trl. JAMA. 2005 Jul 6;294(1):56-65. do 10.1001/jama.294.1.56. Blatt DH, Pryor WA. Hh-dosage vam E supplementatn and all-cause mortaly. Ann tern Med. 2005 Jul 19;143(2):150-1; author reply 156-8. do 10.7326/0003-4819-143-2-200507190-00018. No abstract avaable. McDonald SR, Sohal RS, Forster MJ. Concurrent admtratn of coenzyme Q10 and alpha-tocopherol proves learng aged me. Free Rad Bl Med. 2005 Mar 15;38(6):729-36. do 10.1016/j.freeradbmed.2004.11.014. Mler ER 3rd, Pastor-Barrso R, Dalal D, Rmersma RA, Appel LJ, Guallar E. Meta-analys: hh-dosage vam E supplementatn may crease all-cause mortaly. Ann tern Med. 2005 Jan 4;142(1):37-46. do 10.7326/0003-4819-142-1-200501040-00110. Epub 2004 Nov 10. Parkson Study Group. Effects of tocopherol and deprenyl on the progressn of daby early Parkson's dease. N Engl J Med. 1993 Jan 21;328(3):176-83. do 10.1056/NEJM199301213280305. Effects of Coenzyme Q10 in Parkinson Disease - Phase III

Online report